RADNOR, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Company management will present at 5:15PM PT on Wednesday, January 15th, 2025. A live webcast of the event will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for at least 30 days thereafter. About CertaraCe ...

RADNOR, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today showcases its impact on research by celebrating more than 100 publications secured in 2024 as well as the 12 Certara scientists included on the 2024 Stanford/Elsevier list, which highlights the top 2% of the most cited scientists across the globe. Stanford/Elsevier's Top 2% Scientist RankingNow in its 7th iteration, the Stanford/Elsevier's Top 2% Scientist Ranking list inclu ...

Certara, Inc. (NASDAQ:CERT) Q3 2024 Earnings Conference Call November 6, 2024 5:00 PM ET Company Participants David Deuchler - IR, Gilmartin Group LLC William Feehery - CEO John Gallagher - CFO Conference Call Participants Jeff Garro - Stephens Inc. Max Smock - William Blair Ahmed Muhammad - Leerink Partners Kyle Crews - UBS Luke Sergott - Barclays Operator Good day, and thank you for standing by. Welcome to the Certara Third Quarter Earnings Conference Call. At this time, all participants are in a listen-o ...

Table of Contents _________________________ _________________________ _________________________ _________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ ...

Exhibit 99.1 Certara Reports Third Quarter 2024 Financial Results Updates Full Year 2024 Financial Guidance RADNOR, PA — November 6, 2024-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024. Third Quarter Highlights: • Revenue was $94.8 million, compared to $85.6 million in the third quarter of 2023, representing growth of 11%. • Software revenue was $35.9 million, compared to $31.3 million in the ...

RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024. Third Quarter Highlights: Revenue was $94.8 million, compared to $85.6 million in the third quarter of 2023, representing growth of 11%. Software revenue was $35.9 million, compared to $31.3 million in the third quarter of 2023, representing growth of 15%.Services revenue was $58.9 million, compared to ...

RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephens Annual Investment Conference. Company management will present at 10:00AM CT on Thursday, November 21st, 2024. A live webcast of the event will be available on Certara's investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter. About Certara Certara ...

RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. "We are excited to welcome an accomplished pharmaceutical industry leader with a track record of success to Certara's Board," said William F. Feehery, PhD, CEO of Certara. "John's expertise in artificial intelligence, data science, and life science will provide immense val ...

RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A ...

RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has completed the acquisition of Chemaxon. Chemaxon develops leading scientific informatics software products used by the life sciences industry for insilico research. Certara develops advanced modeling and biosimulation solutions used to predict the pharmacokinetic and pharmacodynamic properties of large and small molecules. "Combining Chemaxon's expertise with ...